The Agency shall support the monitoring of the Eudravigilance database by providing national competent authorities with access to the following information:
data outputs and statistical reports allowing a review of all adverse reactions reported to the Eudravigilance database in relation to an active substance or a medicinal product;
customised queries supporting the evaluation of individual case safety reports and case series;
customised grouping and stratification of data enabling the identification of patient groups with a higher risk of occurrence of adverse reactions or with a risk of a more severe adverse reaction;
statistical signal detection methods.
The Agency shall also ensure appropriate support for the use of the Eudravigilance database by marketing authorisation holders.